Success Metrics

Clinical Success Rate
90.0%

Based on 9 completed trials

Completion Rate
90%(9/10)
Active Trials
3(19%)
Results Posted
78%(7 trials)
Terminated
1(6%)

Phase Distribution

Ph phase_1
2
13%
Ph phase_2
4
25%
Ph phase_3
9
56%

Phase Distribution

2

Early Stage

4

Mid Stage

9

Late Stage

Phase Distribution15 total trials
Phase 1Safety & dosage
2(13.3%)
Phase 2Efficacy & side effects
4(26.7%)
Phase 3Large-scale testing
9(60.0%)

Highest Phase Reached

Phase 3

Trial Status & Enrollment

Completion Rate

90.0%

9 of 10 finished

Non-Completion Rate

10.0%

1 ended early

Currently Active

3

trials recruiting

Total Trials

16

all time

Status Distribution
Active(5)
Completed(9)
Terminated(1)
Other(1)

Detailed Status

Completed9
Recruiting2
Enrolling by invitation2
unknown1
Active, not recruiting1
Terminated1

Development Timeline

Analytics

Development Status

Total Trials
16
Active
3
Success Rate
90.0%
Most Advanced
Phase 3

Trials by Phase

Phase 12 (13.3%)
Phase 24 (26.7%)
Phase 39 (60.0%)

Trials by Status

recruiting213%
unknown16%
active_not_recruiting16%
completed956%
terminated16%
enrolling_by_invitation213%

Recent Activity

3 active trials
Showing 5 of 16
recruitingphase_3

A Study to Evaluate Tradipitant on Treating Nausea and Vomiting Induced by GLP-1R Agonist Use

NCT07446439
active_not_recruitingphase_3

Motion Delos: An Open Label Safety and Efficacy of Tradipitant in Participants Affected by Motion Sickness

NCT06138613
enrolling_by_invitationphase_2

Tradipitant for Functional Dyspepsia

NCT05653310
completedphase_2

A Study to Measure the Effects of Using Tradipitant on Nausea and Vomiting After GLP-1R Agonist Use

NCT06804603
unknown

Single-Patient Expanded Access Protocol for Tradipitant In A Single Patient With Gastroparesis

NCT04474990
View all 16 trials

Clinical Trials (16)

Showing 16 of 16 trials
NCT07446439Phase 3

A Study to Evaluate Tradipitant on Treating Nausea and Vomiting Induced by GLP-1R Agonist Use

Recruiting
NCT06138613Phase 3

Motion Delos: An Open Label Safety and Efficacy of Tradipitant in Participants Affected by Motion Sickness

Active Not Recruiting
NCT05653310Phase 2

Tradipitant for Functional Dyspepsia

Enrolling By Invitation
NCT06804603Phase 2

A Study to Measure the Effects of Using Tradipitant on Nausea and Vomiting After GLP-1R Agonist Use

Completed
NCT04474990

Single-Patient Expanded Access Protocol for Tradipitant In A Single Patient With Gastroparesis

Unknown
NCT04028492Phase 3

Evaluating the Safety and Efficacy of Tradipitant vs. Placebo in Idiopathic and Diabetic Gastroparesis

Completed
NCT03772340Phase 2

Motion Sifnos: A Study to Investigate the Efficacy of Tradipitant in Subjects Affected by Motion Sickness

Completed
NCT05903924Phase 3

Motion Serifos: A Study to Investigate the Efficacy of Tradipitant in Participants Affected by Motion Sickness

Completed
NCT06836557Phase 3

Open Label Safety Study of Tradipitant in Idiopathic and Diabetic Gastroparesis

Recruiting
NCT04327661Phase 3

Motion Syros: A Study to Investigate the Efficacy of Tradipitant in Subjects Affected by Motion Sickness

Completed
NCT02651714Phase 2

Tradipitant in Treatment-resistant Pruritus Associated With Atopic Dermatitis

Completed
NCT04140695Phase 3

Evaluating the Effects of Tradipitant vs. Placebo in Atopic Dermatitis (EPIONE2)

Terminated
NCT03568331Phase 3

Evaluating the Effects of Tradipitant vs. Placebo in Atopic Dermatitis (EPIONE)

Completed
NCT04849559Phase 1

Effects of Tradipitant on Satiation, Gastric Volume, Gastric Accommodation, and Gastric Emptying in Healthy Volunteers

Completed
NCT04326426Phase 3

ODYSSEY: A Study to Investigate the Efficacy of Tradipitant in Treating Severe or Critical COVID-19 Infection

Enrolling By Invitation
NCT02621385Phase 1

Study to Assess the Effect of Multiple Doses of Tradipitant on CYP3A4 Using Midazolam as a Substrate in Healthy Subjects

Completed

All 16 trials loaded

Drug Details

Intervention Type
DRUG
Total Trials
16